Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg
TRACK_001
Phase 3 small_molecule active
Quick answer
Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg for Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease. is a Phase 3 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active